ArticleMolecular neurobiology2026
Cerebrospinal Fluid Metabolites Mediate Immune Cell Effects on Chronic Pain.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundWhile immune cells have been implicated in chronic pain (CP), the causal relationships between immune cells and CP across different body regions, as well as the potential mediating role of cerebrospinal fluid (CSF) metabolites on CP, remain unclear.
methodsIn this study, we inspected the causal relationship between circulating immune cell subsets and CP in the neck/shoulder, back, hip, and knee by using a two-sample Mendelian randomization (MR) analysis. In addition, a two-step MR approach was applied to assess the mediating role of CSF metabolites linking immune cells and CP, identifying potential mediators and quantifying their mediation effects. The robustness of the MR findings was assessed according to comprehensive sensitivity analyses.
resultsMR analysis revealed 76 immune cells were strongly associated with CP across four regions (neck/shoulder, back, hip, and knee), along with 40 CSF metabolites significantly linked to CP. All associations demonstrated no evidence of reverse causation. In the two-step MR mediation analysis, the following potential mediators were identified: (1) For chronic neck/shoulder pain (CNP): 3-Hydroxy-3-methylglutarate (12.9% mediation proportion) for IgD⁻ CD27⁻ absolute cell count (AC), and X-18887 for both CD16 on CD14⁺ CD16⁺ monocytes (5.0%) and IgD on IgD⁺ CD38⁻ cells (4.3%); (2) For chronic back pain (CBP): X-14056 for CD20 on IgD⁺ CD38bright cells (22.7%) and CD20 on transitional B cells (17.6%), and Beta-hydroxyisovalerate (8.6%) for CD3⁻ lymphocyte AC; (3) For chronic knee pain (CKP): Phenol sulfate for CD45RA on naive CD8br cells (20.0%) and CD20 on unsw mem cells (16.7%); Arginine for CD27 on memory B cells (13.6%); and N-Acetyl-aspartyl-glutamate (13.0%) for IgD on IgD⁺ CD38⁻ cells. The robustness of these findings was further confirmed through sensitivity analyses.
conclusionsThese findings underscore the mediating role of CSF metabolites in the immune cell-chronic pain axis, providing mechanistic insights into CP pathogenesis and potential therapeutic targets across distinct pain regions.
Indexed as
Identifiers
42730813What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.